FindTrial
Sign In

Effects of esketamine for epidural labor analgesia on EC50 and EC95 of ropivacaine

Effects of esketamine for epidural labor analgesia on EC50 and EC95 of ropivacaine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100054348
Enrollment
Unknown
Registered
2021-12-14
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Group 1:esketamine 0.2mg/ml
Group 2:esketamine 0.3mg/ml
Group 3:esketamine 0.4mg/ml
Group 4:esketamine 0.5mg/ml
Control group:none

Sponsors

Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Full-term (>=37 weeks old), singleton, spontaneous childbirth, cervical dilation of 2-5 cm during the latent stage of labor, and women with painful uterine contractions requiring epidural labor analgesia.

Exclusion criteria

Exclusion criteria: Women with contraindications to epidural analgesia, preeclampsia, diabetes mellitus, congenital fetal abnormalities, and co-morbidities such as cardiomyopathy, liver disease, and renal insufficiency.

Design outcomes

Primary

MeasureTime frame
ED50 and ED95 of ropivacaine in different group;—

Countries

China

Contacts

Public ContactChen Xinzhong

Obstetrics and Gynecology Hospital Affiliated to Zhejiang University School of Medicine

chenxinz@zju.edu.cn+86 13575738058

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026